SCHEMBL24697356

SCHEMBL24697356

Cc1[nH]c(-c2ccccc2)cc1S(=O)(=O)Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.54
KDM4E B2RXH2 9/20 0.47
CYP2C9 P11712 2/20 0.47
CYP3A4 P08684 2/20 0.47
POLB P06746 1/20 0.47
HPGD P15428 6/20 0.45
ALDH1A1 P00352 6/20 0.45
GAA P10253 5/20 0.45
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.42
HSD17B10 Q99714 4/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 3/20 0.41
TP53 P04637 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TAS2R38 P59533 1/20 0.40
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24697352 0.82 BRD4 (0.54) BRD4KDM4ECYP2C9CYP3A4POLB
SCHEMBL2215320 0.73 BRD4 (0.75) BRD4KDM4EALDH1A1MAPTTAS2R38
SCHEMBL21757291 0.72 BRD4 (0.55) BRD4KDM4ECYP2C9CYP3A4POLB
SCHEMBL16976741 0.71 PDE4A (0.55) BRD4KDM4EHPGDALDH1A1GAA
SCHEMBL1450398 0.70 BRD4 (0.71) BRD4KDM4EALDH1A1MAPTTAS2R38
SCHEMBL7173993 0.70 BRD4 (1.00) BRD4ALDH1A1MAPT
SCHEMBL11016316 0.69 BRD4 (0.56) BRD4KDM4EHPGDALDH1A1GAA
SCHEMBL6957694 0.69 BRD4 (0.56) BRD4KDM4EHPGDALDH1A1GAA
SCHEMBL7328512 0.69 RAB9A (0.66) BRD4KDM4ECYP2C9CYP3A4POLB
SCHEMBL11494371 0.69 HTR6 (0.45) BRD4KDM4EPOLBHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240299385-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS REWIND THERAPEUTICS NV (BE) 2024-09-12 US disclosed
EP-4347558-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS ReWind Therapeutics NV (BE) 2024-04-10 EP disclosed
CN-117794898-A 3-pyrrolylsulfonamide compounds as GPR17 antagonists 瑞文德医疗公众有限公司 2024-03-29 CN disclosed
WO-2022254027-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS REWIND THERAPEUTICS NV (BE) 2022-12-08 WO disclosed
WO-2022254027-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS REWIND THERAPEUTICS NV (BE) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299385-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS GPR3, GPR27, GPR65 BRD4 3086/4885KDM4E 3712/4885CYP2C9 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.